Melatonin Strip Dosage: Why More Isn't Better

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Oral melatonin bioavailability is low and highly variable — roughly 3 to 33 percent across studies — due to extensive hepatic first-pass metabolism (Harpsøe et al., 2015; Andersen et al., 2016). For the EFSA-authorized health claim of reduced sleep onset latency, only 1 mg taken close to bedtime is required, and higher doses are not correlated with greater effect (EFSA, 2011). Sublingual delivery partly bypasses first-pass metabolism, raising serum melatonin from a smaller dose (Bartoli et al., 2023). The MIHIYO Labs Sleep-Support oral dissolving strip (ODS) is formulated at the low end of this evidence-supported range, to match physiologic nighttime melatonin without overshooting it.

How much melatonin do you actually need?

The clinical answer: 0.3 to 1 mg taken close to bedtime is sufficient to reduce sleep onset latency in healthy adults. The European Food Safety Authority's official scientific opinion (EFSA Journal, 2011, DOI 10.2903/j.efsa.2011.2241) authorizes the health claim "Melatonin helps to reduce the time to fall asleep" at a dose of 1 mg consumed close to bedtime. The same opinion explicitly notes that higher doses are not correlated with an improved effect on sleep onset latency.

That second sentence is the part most US melatonin marketing ignores. Walk into any pharmacy and you will find melatonin sold at 3 mg, 5 mg, 10 mg, even 20 mg per dose — concentrations that produce serum melatonin levels 10 to 60 times higher than the body produces endogenously at night, with no additional benefit for sleep onset and a measurable increase in next-day grogginess and other effects.

This article explains the pharmacology behind why "more is not better" for melatonin, why oral bioavailability is so variable, and why the strip format changes the dosing math.

Why oral melatonin bioavailability is so low and so variable

Melatonin is a small lipid-soluble indolamine. Once swallowed, it absorbs efficiently from the gut, but then runs into the liver — where it is rapidly metabolized by CYP1A2 to 6-hydroxymelatonin before it ever reaches the rest of the body.

A 2015 systematic review by Harpsøe et al. (Eur J Clin Pharmacol, PMID 26008214) compiled 22 published pharmacokinetic studies and found absolute oral bioavailability of melatonin in the range of 9 to 33 percent, with extreme inter-individual variability in both Cmax and AUC. A separate intravenous-versus-oral PK study by Andersen et al. (BMC Pharmacol Toxicol, 2016, PMC4759723) reported absolute oral bioavailability as low as 3 percent in some subjects, with ten-fold differences between participants.

The variability is not noise. It tracks identifiable factors:

  • CYP1A2 activity, which is induced by smoking and oral contraceptives and inhibited by caffeine and fluvoxamine
  • Age, with reduced clearance in older adults
  • Sex, with female subjects often showing two-to-three-fold higher AUC than males at the same oral dose
  • Feeding status, which alters gastric emptying and splanchnic blood flow

In practice, this means a 5 mg oral capsule does not deliver "5 mg of melatonin" to your bloodstream. It delivers somewhere between 0.15 mg and 1.65 mg of bioavailable melatonin, depending on which person is taking it and under what conditions. That uncertainty — by itself — is one reason higher labeled doses do not produce reliably stronger effects.

The dose-response paradox: why higher does not mean better

Endogenous nocturnal serum melatonin in healthy adults peaks at roughly 50 to 200 pg/mL (picograms per milliliter) — that is, 0.05 to 0.2 nanograms per milliliter. A 1 mg oral dose typically raises serum melatonin to roughly 500 to 2,000 pg/mL, which is already 5 to 40 times the physiological peak. A 3 mg dose pushes that into the 5,000 pg/mL range. A 10 mg dose can push serum melatonin into the 60,000 pg/mL range — three orders of magnitude above what your pineal gland produces on its busiest night.

The MT1 and MT2 melatonin receptors that mediate sleep-promoting effects saturate at low concentrations. Once they are bound, additional melatonin in circulation does not produce additional receptor-mediated effect. This is the pharmacological reason the EFSA panel was direct: higher doses do not improve sleep onset latency.

The supporting clinical work goes back decades. Zhdanova et al. (Sleep, 1996, PMID 8843534) gave 0.3 mg and 1.0 mg melatonin to young healthy adults two to four hours before bedtime. Both doses reduced sleep onset latency. The 0.3 mg dose raised serum melatonin to roughly the physiological nighttime level; the 1.0 mg dose pushed it modestly higher. Neither dose impaired next-day mood or performance. A follow-up study in older adults with insomnia (Zhdanova et al., JCEM, 2001, PMID 11600532) again showed that low physiological doses were effective.

The trade-offs of supraphysiological dosing are documented:

  • Next-day grogginess, attributable to prolonged elevation of serum melatonin into the morning window
  • Lower core body temperature sustained beyond physiological need
  • Vivid dreams reported in a subset of users
  • Disruption of endogenous melatonin rhythm with chronic high-dose use

None of these are catastrophic, but they are unnecessary if a smaller dose produces the same sleep onset effect.

Serum melatonin concentration by oral dose, against the endogenous nighttime range A 0.3 mg dose raises serum melatonin into the endogenous nighttime range of 50 to 200 picograms per milliliter. A 1 mg dose elevates it 5 to 40 times above that range. A 10 mg dose elevates it hundreds of times higher, well past the saturation point of MT1 and MT2 receptors. Serum melatonin Cmax by oral dose (log scale) Approximate values from Harpsøe et al., 2015 and Andersen et al., 2016 Serum melatonin Cmax (pg/mL, log) Oral melatonin dose (mg) 50 200 1,000 5,000 60,000 Endogenous nighttime range (50–200 pg/mL) Supraphysiological — receptors saturated 0.3 1 3 5 10 ~150 ~1,000 ~3,000 ~5,000 ~60,000 EFSA 1 mg Above ~1 mg, additional dose does not produce additional receptor effect (EFSA, 2011)

What sublingual delivery actually changes

For melatonin specifically — unlike caffeine — the route of delivery changes both how much and how fast the dose reaches circulation, because melatonin's first-pass metabolism is the dominant variable in the swallowed-dose pharmacokinetics.

A 2023 single-dose crossover study by Bartoli et al. (Drugs in R&D, PMID 37438493) compared an immediate-release sublingual melatonin spray against an oral prolonged-release tablet in healthy male volunteers. The sublingual route produced significantly higher Cmax and AUC than the swallowed prolonged-release form. An earlier crossover study from the same group (J Bioequiv Availab, 2012) using a 5 mg dose showed Cmax of roughly 17 ng/mL for the oral spray versus 12 ng/mL for the tablet, with significantly higher AUC for the spray (p = 0.045).

Parameter Oral tablet Sublingual spray Source
Absolute bioavailability range 3–33% partially recovered Harpsøe 2015; Bartoli 2023
Relative Cmax (5 mg dose) reference (~12 ng/mL) ~17 ng/mL (40% higher) Bartoli 2012
First-pass loss substantial partly bypassed Lane & Moss 1985; Bartoli 2023
Tmax similar (~30–45 min) similar (~30–45 min) Bartoli 2012
Inter-individual variability very high reduced (less GI dependent) Harpsøe 2015
Labeled melatonin dose versus actually absorbed dose, oral capsule versus sublingual route A 5 mg oral melatonin capsule delivers between 0.15 and 1.65 milligrams of bioavailable melatonin to the bloodstream because oral bioavailability ranges from 3 to 33 percent and varies extensively between individuals. Sublingual delivery partly bypasses first-pass hepatic metabolism and produces a tighter, more predictable absorbed range. Label dose ≠ delivered dose Oral melatonin bioavailability varies 3–33% between individuals (Harpsøe et al., 2015) 0 1 2 3 4 5 Melatonin (mg) 5 mg oral capsule (label dose) label = 5 mg 0.15 – 1.65 mg actually absorbed ~11x variability between people 1 mg sublingual strip (label dose) label = 1 mg ~0.4–0.7 mg tighter, more predictable absorption A smaller, well-absorbed dose hits the receptor target — without the variability or overshoot.

The pharmacological consequence is that a sublingual or buccal route can produce serum melatonin in the same physiological range from a smaller dose. That matters not because "more is reaching the blood" is automatically a good thing — it is not, since the receptors saturate — but because a smaller, more reliably absorbed dose can hit the right serum window without the variability and overshoot that comes with high-dose oral capsules.

The point of sublingual melatonin is dose precision, not dose maximization.

What this means for the MIHIYO Sleep-Support strip

The MIHIYO Labs Sleep-Support ODS is formulated to dissolve against the inner cheek or under the tongue over approximately 60–90 seconds, delivering a low milligram dose engineered to match physiological nighttime melatonin once mucosal absorption is accounted for.

I want to be direct about what the published literature does and does not support here. Every citation in this article is on melatonin formulations from independent research groups — capsules, prolonged-release tablets, oral sprays, sublingual sprays — not on the MIHIYO product. The mechanism is general; the specific PK profile of our strip would require a head-to-head trial we do not currently have. What the literature supports is the dosing philosophy: low, well-timed doses delivered through a route that partly bypasses first-pass metabolism are more aligned with both the receptor pharmacology and the EFSA position than high-dose oral capsules.

The practical recommendation that follows from the pharmacology: take the strip 30 to 60 minutes before intended sleep, place it against the buccal or sublingual tissue, and leave it alone. Do not chew. Do not chase it with water. The strip works as the polymer matrix dissolves and the melatonin crosses the mucosa.

For related context on why dosage form matters across other supplement categories, see our foundational article on sublingual versus oral absorption. For melatonin's interaction with the broader sleep architecture, including the limits of melatonin alone, see the future article on the case for water-free dosing.

Where this approach has limits

Melatonin is not a sedative. It does not force sleep onset; it shifts the body's biological readiness to sleep by acting on MT1 and MT2 receptors in the suprachiasmatic nucleus. For someone whose sleep onset problem is rumination, anxiety, pain, or environmental disruption, melatonin will not fix the underlying issue regardless of dose or route.

Melatonin has weak evidence for chronic insomnia in adults under age 55 (Brzezinski et al., Sleep Med Rev, 2005, PMID 15649737). The strongest evidence is for sleep onset latency in healthy individuals, jet lag, and age-related insomnia in older adults — populations and use cases where physiological nighttime melatonin is reduced or out of phase with the desired sleep window.

Melatonin should not be used continuously without intent. The endogenous rhythm responds to exogenous administration, and chronic supraphysiological dosing has a different risk profile than occasional low-dose use to address a specific scheduling problem (jet lag, shift change, occasional sleep onset difficulty).

Pediatric, pregnancy, and chronic-condition use of melatonin involves considerations beyond the scope of this article — those decisions belong with a clinician who has your full history.

The bottom line on melatonin strip dosage

The pharmacology of melatonin makes a clear case for low, precise doses delivered through a route that minimizes first-pass loss. The EFSA-authorized claim is built around 1 mg; clinical research confirms efficacy at doses as low as 0.3 mg; and supraphysiological doses do not improve sleep onset latency while introducing avoidable next-day effects. A sublingual melatonin strip is the dosage form that most directly aligns with this evidence — small dose, predictable absorption, no overshoot. The wrong question is "how much melatonin should I take?" The right question is "how do I match my serum melatonin to what my body would produce on a normal night?"

References

  1. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal. 2011;9(6):2241. DOI: 10.2903/j.efsa.2011.2241. <https://efsa.onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2011.2241>
  1. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901-909. PMID: 26008214. <https://pubmed.ncbi.nlm.nih.gov/26008214/>
  1. Andersen LP, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H, Rosenberg J, Gögenur I. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol. 2016;17:8. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4759723/>
  1. DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40(7):781-784. PMID: 10883420. <https://pubmed.ncbi.nlm.nih.gov/10883420/>
  1. Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab. 1985;61(6):1214-1216. PMID: 4055987. <https://pubmed.ncbi.nlm.nih.gov/4055987/>
  1. Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C, Matheson JK, Schomer DL. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995;57(5):552-558. PMID: 7768078. <https://pubmed.ncbi.nlm.nih.gov/7768078/>
  1. Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19(5):423-431. PMID: 8843534. <https://pubmed.ncbi.nlm.nih.gov/8843534/>
  1. Zhdanova IV, Wurtman RJ, Regan MM, Taylor JA, Shi JP, Leclair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86(10):4727-4730. PMID: 11600532. <https://pubmed.ncbi.nlm.nih.gov/11600532/>
  1. Bartoli AN, Marchesi N, Pascale A, Quaccini A, Govoni S. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers. Drugs in R&D. 2023. PMID: 37438493. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10439092/>
  1. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9(1):41-50. PMID: 15649737. <https://pubmed.ncbi.nlm.nih.gov/15649737/>

0 comments

Leave a comment

Please note, comments need to be approved before they are published.